40516-31-2 Usage
Uses
Used in Pharmaceutical Industry:
4-CHLORO-7-TRIFLUORO METHOXYQUINOLINE is used as a building block for the synthesis of pharmaceutical drugs due to its unique structure and properties that can be leveraged to create novel drug candidates with potential therapeutic effects.
Used in Chemical Research:
4-CHLORO-7-TRIFLUORO METHOXYQUINOLINE is utilized as a reagent in organic synthesis and chemical research, providing a versatile tool for scientists to explore new chemical reactions and pathways, contributing to the advancement of chemical knowledge and technology.
Used in Medicinal Chemistry:
4-CHLORO-7-TRIFLUORO METHOXYQUINOLINE is employed in the field of medicinal chemistry for its potential biological activity, which can be harnessed to develop new therapeutic agents with specific targets and mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 40516-31-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,5,1 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 40516-31:
(7*4)+(6*0)+(5*5)+(4*1)+(3*6)+(2*3)+(1*1)=82
82 % 10 = 2
So 40516-31-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H5ClF3NO/c11-8-3-4-15-9-5-6(1-2-7(8)9)16-10(12,13)14/h1-5H
40516-31-2Relevant academic research and scientific papers
COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE
-
Page/Page column 63, (2018/03/09)
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
NOVEL QUINOLINE DERIVATIVES
-
Page/Page column 92, (2008/06/13)
The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
